



Editorial, *Journal of Clinical Immunology*

Jean-Laurent Casanova^{1,2,3,3,4,5} · Vincent Bonagura^{6,7}

Published online: 15 October 2019

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Dear Friends,

We write to share good news: our journal is thriving. Since we focused its content on inborn errors of immunity (IEI), as stressed by its novel subtitle [1], we have received more and more papers each year, the quality and diversity of which are steadily increasing. Our published papers have also received increasing international attention, not only on social media but also in terms of downloads and citations. Importantly, we have published papers written by colleagues who work at the four corners of the globe. The JoCI is truly becoming the international journal in the field of IEI. Admittedly, there is no other international journal exclusively devoted to our field!

We encourage you to further help us make this *Journal* the international forum of our community. While we strive to restrict “Original Articles” to the publication of series of patients, clinical breakthroughs, or experimental discoveries, we encourage you to submit case reports or findings of more limited scope as “Letters to the Editor.” Good examples of important “Original Articles” include not only the IUIS Classifications of IEI [2, 3], which are widely read and cited, but also the first report of hematopoietic stem cell transplantation in patients with CARD9 deficiency [4]. This is not to say that the “Letters to the Editor” are not also significant. There are countless examples of exciting letters, all of which cast new light on one or another IEI.

In addition, our two other series have had great success. “How I Treat” reviews have been acclaimed as having been of great practical help worldwide [5, 6]. The “CME Reviews” have attracted enormous attention, which is not surprising as they have been written by the very best experts in each field, whom we want to thank warmly for their contribution to the journal [7–20]. We are thrilled to say that we will soon launch a new series, entitled “Conversations with Founders of the Field.” Max Cooper, who recently received a long overdue Lasker Award, has most generously agreed to be the first interviewee. We will solicit other pioneers in our field and we are confident that these conversations will be of significant interest to our readers.

It is worth noting that the JoCI is not locked into these four or five well-defined formats. We invite colleagues to write editorials, as we do ourselves, for instance to highlight a JoCI paper of particular interest [21, 22]. We are also open to unsolicited editorials and even contributions related to IEI that are written in other formats, such as remembrances of major figures in our field who have recently passed [23–25]. A superb historical piece written by Yanick Crow and the late Ion Gresser neatly illustrates the openness of the journal [26]. In turn, this paper has been read almost as often as the two IUIS classifications, at odds with the widely held view that history of science is only of interest to a handful of investigators.

Authors, referees, and readers make the journal what it is. The JoCI also benefits from the tireless input of a fantastic group of Associate Editors, to whom we would like to express our sincerest gratitude. The JoCI would not have become what it is now without them. We assign most of the submitted papers to them. They evaluate their merits, select referees who provide helpful and detailed reviews of the manuscripts our authors submit to the JoCI, and they make final editorial decisions with us. All published manuscripts have involved either of us and at least one Associate Editor. Beyond the Associate Editors, we benefit from another group of active supporters and advisers in the Editorial Board at large, as well as the Continental and National Societies that have joined us. We warmly thank all of them.

✉ Jean-Laurent Casanova
casanova@mail.rockefeller.edu

- ¹ The Rockefeller University, New York, NY, USA
- ² Howard Hughes Medical Institute, New York, NY, USA
- ³ INSERM, Imagine Institute, Paris, France
- ⁴ Paris Descartes University, Imagine Institute, Paris, France
- ⁵ Necker Hospital for Sick Children, Paris, France
- ⁶ The Feinstein Institute for Medical Research, Manhasset, NY, USA
- ⁷ Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA

References

- Casanova J, Bonagura V. *J Clin Immunol*. 2018;38(4):445–6.
- Picard C, Gaspar BH, Al-Herz W, Bousfiha A, Casanova J-L, Chatila T, et al. International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity. *J Clin Immunol*. 2018;38(1):96–128.
- Bousfiha A, Jeddane L, Picard C, Ailal F, Bobby Gaspar H, Al-Herz W, et al. The 2017 IUIS phenotypic classification for primary immunodeficiencies. *J Clin Immunol*. 2018;38(1):129–43.
- Queiroz-Telles F, Mercier T, Maertens J, Sola CBS, Bonfim C, Lortholary O, et al. Successful allogeneic stem cell transplantation in patients with inherited CARD9 deficiency. *J Clin Immunol*. 2019;39(5):462–9.
- Shouval DS, Kowalik M, Snapper SB. The treatment of inflammatory bowel disease in patients with selected primary immunodeficiencies. *J Clin Immunol*. 2018;38(5):579–88.
- Kohn DB, Gaspar HB. How we manage adenosine deaminase-deficient severe combined immune deficiency (ADA SCID). *J Clin Immunol*. 2017;37(4):351–6.
- Georgiev P, Charbonnier L-M, Chatila TA. Regulatory T cells: the many faces of Foxp3. *J Clin Immunol*. 2019;39(7):623–40.
- Heusinkveld LE, Majumdar S, Gao J-L, McDermott DH, Murphy PM. WHIM syndrome: from pathogenesis towards personalized medicine and cure. *J Clin Immunol*. 2019;39(6):532–56.
- Pöyhönen L, Bustamante J, Casanova J-L, Jouanguy E, Zhang Q. Life-threatening infections due to live-attenuated vaccines: early manifestations of inborn errors of immunity. *J Clin Immunol*. 2019;39(4):376–90.
- Booshehri LM, Hoffman HM. CAPS and NLRP3. *J Clin Immunol*. 2019;39(3):277–86.
- Tangye SG, Bier J, Lau A, Nguyen T, Uzel G, Deenick EK. Immune dysregulation and disease pathogenesis due to activating mutations in *PIK3CD*—the Goldilocks’ effect. *J Clin Immunol*. 2019;39(2):148–58.
- Delmonte OM, Schuetz C, Notarangelo LD. RAG deficiency: two genes, many diseases. *J Clin Immunol*. 2018;38(6):646–55.
- Corvilain E, Casanova J-L, Puel A. Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults. *J Clin Immunol*. 2018;38(6):656–93.
- Rieux-Laucat F, Magérus-Chatinet A, Neven B. The autoimmune lymphoproliferative syndrome with defective FAS or FAS-ligand functions. *J Clin Immunol*. 2018;38(5):558–68.
- Meyts I, Aksenitjevič I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. *J Clin Immunol*. 2018;38(5):569–78.
- Candotti F. Clinical manifestations and pathophysiological mechanisms of the Wiskott-Aldrich syndrome. *J Clin Immunol*. 2018;38(1):13–27.
- Gallo V, Cirillo E, Giardino G, Pignata C. FOXN1 deficiency: from the discovery to novel therapeutic approaches. *J Clin Immunol*. 2017;37(8):751–8.
- Bradford KL, Moretti FA, Carbonaro-Sarracino DA, Gaspar HB, Kohn DB. Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations. *J Clin Immunol*. 2017;37(7):626–37.
- Boisson B, Puel A, Picard C, Casanova J-L. Human $\text{I}\kappa\text{B}\alpha$ gain of function: a severe and syndromic immunodeficiency. *J Clin Immunol*. 2017;37(5):397–412.
- Klein C. Kostmann’s disease and HCLS1-associated protein X-1 (HAX1). *J Clin Immunol*. 2017;37(2):117–22.
- Meyts I. Hematopoietic stem cell transplantation in CARD9 deficiency: knight in shining armor? *J Clin Immunol*. 2019;39(5):459–61.
- Bonagura VR. Successful rituximab treatment for lymphoma, secondary immunodeficiency causing debilitating sinusitis: underlying primary immunodeficiency disease, and alternative treatments to improve the quality of life? *J Clin Immunol*. 2019;39(3):229–30.
- Aiuti A, Quinti I. In Memoriam: Fernando Aiuti, MD (June 8, 1935–January 9, 2019). *J Clin Immunol*. 2019;39(2):142–3.
- Lankester A, Heidt P, Rümke H, Bredius R, van Tol M. In Memoriam: Prof. Dr. J.M.J.J. Vossen (1937–2019). *J Clin Immunol*. 2019;39(6):530–1.
- Condino-Neto A. Prof. Dr. Beatriz Tavares Costa-Carvalho Obituary. *J Clin Immunol*. 2019;39(6):529.
- Crow YJ, Lebon P, Casanova J-L, Gresser I. A brief historical perspective on the pathological consequences of excessive type I interferon exposure in vivo. *J Clin Immunol*. 2018;38(6):694–8.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.